# Ipamorelin: research overview

> Ipamorelin: Research Overview — Growth Hormone Axis Research Peptides — steroidnpeptides — Ipamorelin among the Growth Hormone Axis research peptides: a selective ghrelin-receptor agonist whose only Phase 2 trial missed its endpoint. Mechanism, human pharmacokinetics, animal findings and safety gaps, all cited.

**01 · GHRELIN-RECEPTOR SIDE OF THE AXIS**

Five amino acids, one selective receptor, and a published human record consisting of a single failed Phase 2 trial and one pharmacokinetic study.

## The short version

Ipamorelin is a synthetic peptide five amino acids long. It works on the *ghrelin receptor* — the receptor the body's hunger hormone uses — and switching that receptor on in the pituitary gland produces a short burst of growth hormone.

Its distinguishing feature is what it does not do. Older peptides in the same family also pushed up cortisol, prolactin and ACTH; ipamorelin, in the characterisation literature, does not meaningfully raise any of them. That selectivity is why it became the reference compound of its class.

Human data are unusually scarce. There is one published Phase 2 trial, in adults recovering from bowel surgery, and it missed its primary endpoint [3]. There is one human pharmacokinetic study, in eight volunteers per dose level [4]. Everything else on the public record is animal work: rats, mice, ferrets [1][5]. Nothing published supports the uses the compound is marketed for.

## What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Alpha-aminoisobutyric acid sits at position one; D-2-naphthylalanine and D-phenylalanine at positions three and four confer resistance to the proteases that would otherwise dismantle a chain this short. It was derived from the earlier growth-hormone-releasing peptide GHRP-1 by removing the central Ala-Trp dipeptide. In the older pharmacological literature it appears as NNC 26-0161; commercially it is usually supplied as ipamorelin acetate.

It has never been approved as a drug anywhere. It was investigated for postoperative ileus and abandoned [3]. In 2024 the United States Food and Drug Administration removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following the nominator's withdrawal, and reviewed both the acetate and the free base at the Pharmacy Compounding Advisory Committee meeting of 29 October 2024. It is not an approved bulk substance for compounding, and it is marketed only as a research chemical.

## How it works

Ipamorelin is a selective agonist of the growth hormone secretagogue receptor GHS-R1a — the ghrelin receptor. Activating it on pituitary somatotroph cells triggers a discrete pulse of growth hormone release.

That pathway is distinct from, and complementary to, the growth-hormone-releasing hormone pathway that CJC-1295 and tesamorelin act on. The two receptors converge on the same cell but arrive by different routes, which is the pharmacological basis of the frequently discussed pairing of a ghrelin-receptor agonist with a GHRH analog. It is a mechanistic rationale, not a trial result; the combination has never been studied for any outcome.

GHS-R1a is not confined to the pituitary. It appears on enteric and vagal neurons involved in gastric motility, on pancreatic islet cells where preclinical work shows a direct insulin-releasing effect independent of growth hormone, and in hypothalamic appetite circuitry, where the class carries a well-described orexigenic signal.

The human pharmacokinetics are the clearest thing on the record. In healthy male volunteers given five fifteen-minute intravenous infusions across a dose range of 4.21 to 140.45 nmol/kg, with eight volunteers per dose level, kinetics were dose-proportional: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The growth hormone response peaked at about 0.67 hours — roughly 40 minutes — after dosing, as a single discrete pulse rather than a sustained elevation [4].

## What the research shows

**The one controlled human trial.** A prospective, randomised, placebo-controlled proof-of-concept study enrolled 114 adults undergoing open or laparoscopic bowel resection, who received 0.03 mg/kg intravenously twice daily for up to seven days. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, p=0.15. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm [3]. This is the defining human efficacy and safety anchor for the compound, and what it establishes is that efficacy was not demonstrated.

**Human pharmacokinetics.** Population PK/PD modelling in healthy male volunteers established dose-proportional kinetics, a terminal half-life of approximately 2 hours, and a single growth hormone pulse peaking around 40 minutes post-dose [4].

**Bone growth in rats.** Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided into three daily administrations for fifteen days, raised the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively. Total IGF-1, the IGF binding proteins and bone turnover markers were unchanged [5]. The effect appeared without a measurable shift in systemic IGF-1, which points to a locally acting, pulse-driven skeletal mechanism.

**The most recent in-vivo work.** A 2024 ferret study of cisplatin-induced weight loss and emesis found that intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited body-weight loss by approximately 24% on the last day of the delayed phase, 48 to 72 hours after cisplatin, while producing no anti-emetic effect in either the acute or the delayed phase. Intracerebroventricular anamorelin, a different agent in the same class, reduced acute emesis by 60% in the same model [1]. The weight-loss effect appeared to be peripheral.

**A class-level safety signal.** An integrated preclinical safety-pharmacology study of GSK894281 — a structurally distinct GHS-R1a agonist, not ipamorelin — found dose-dependent myocardial degeneration and necrosis in rats after 28 days of oral dosing, detectable by histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated [2]. Ipamorelin itself was not the tested compound, and no equivalent long-duration cardiovascular study of ipamorelin exists in any species. The finding belongs to the receptor class, and it is the reason chronic systemic dosing of any GHS-R1a agonist is treated as an open safety question rather than a settled one.

## Reported effects, cautions and safety

What follows in this first block is anecdotal, not clinical evidence: a summary of what people using ipamorelin outside any trial report to one another in research-use communities. None of it was measured, controlled or verified; the material involved was of unknown purity and origin; and no amounts are given here or anywhere on this site.

The most frequently reported benefit by a wide margin is sleep — falling asleep faster, sleeping more deeply, waking more rested. More vivid dreams during the earliest weeks are commonly described alongside it and usually reported as transient. Faster recovery between training sessions and reduced soreness form the second cluster. A gradual shift toward a leaner appearance is reported occasionally, described as slow and subtle, and is thoroughly confounded by whatever diet and training the person was already doing.

On the adverse side, a transient facial flush or head-rush shortly after injection is widely described, as are tingling or numbness in the hands and feet, mild puffiness or water retention, increased hunger in the hours after a dose — unsurprising for a ghrelin-receptor agonist — injection-site redness or itching, and occasional lightheadedness. Some community accounts describe the perceived effects fading after several months of uninterrupted use. All of it is self-reported and none of it has been measured.

**Cautions grounded in mechanism and literature.** Growth hormone axis activation raises hepatic IGF-1, and IGF-1 is a well-characterised mitogen. The concern that chronically raising growth hormone pulse amplitude could accelerate proliferative activity in a pre-existing or occult tumour is mechanistic and class-level; no ipamorelin-specific carcinogenicity or tumour-promotion study exists in humans, so the question is open rather than answered.

Growth hormone is a counter-regulatory hormone that reduces peripheral insulin sensitivity. Ipamorelin additionally has a growth-hormone-independent insulinotropic action on pancreatic islet tissue in ex vivo preparations from both normal and diabetic rats. That combination — reduced peripheral sensitivity plus a direct beta-cell effect — makes the net glycaemic result unpredictable in anyone whose glucose handling is already disturbed. No human glycaemic dataset for ipamorelin exists.

Cardiovascular caution rests on the class-level myocardial finding described above [2] together with the fluid retention and cardiomegaly seen in states of growth hormone excess. Appetite and adiposity caution rests on the orexigenic and adipogenic signalling that comes with ghrelin-receptor agonism and is not neutralised by ipamorelin's selectivity for growth hormone over cortisol and prolactin.

The largest caution is the plainest. The entire controlled human safety record consists of a seven-day perioperative intravenous trial in 114 patients [3] and acute single-dose infusions in eight volunteers per dose level [4]. No Phase 3 trial has been run. No long-term human safety database exists. The dominant route in off-label use has no published pharmacokinetic or safety characterisation in humans at all, and the material circulating outside pharmaceutical supply chains is not subject to pharmaceutical quality assurance.

## Where it fits in the growth hormone axis

Ipamorelin occupies the ghrelin-receptor half of this desk. CJC-1295 and tesamorelin both act at the growth-hormone-releasing hormone receptor; ipamorelin arrives at the same pituitary cell through a different door. That complementarity is real pharmacology and is the honest reason the two classes are discussed together.

It is also where the evidence stops. The combination protocols that circulate online rest on separate single-agent pharmacology, never on a trial of the combination for any outcome. Of the three compounds covered here, ipamorelin has the least human evidence and, by a considerable margin, the most marketing. The gap between those two facts is the whole reason to read the primary sources rather than the summaries of them.

Read against tesamorelin, the contrast is stark. Tesamorelin's evidence base is a 52-week programme with hundreds of participants and a regulator-accepted endpoint [17]. Ipamorelin's is one failed trial, one pharmacokinetic study, and a set of animal experiments measuring bone growth in micrometres and chemotherapy weight loss in ferrets [1][5]. Both compounds raise growth hormone. Only one of them has ever been shown to change an outcome anybody cared about, and it was not the one that sells better.

---

A reference desk on the growth hormone axis: it reports what the trials measured and names the species they measured it in, and it covers neither anabolic pharmacology nor any way of obtaining anything.